D. M. Jackman

1.1k total citations
19 papers, 196 citations indexed

About

D. M. Jackman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, D. M. Jackman has authored 19 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in D. M. Jackman's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (8 papers). D. M. Jackman is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (8 papers). D. M. Jackman collaborates with scholars based in United States, Taiwan and Spain. D. M. Jackman's co-authors include Pasi A. Jänne, Lecia V. Sequist, Bruce E. Johnson, Greg J. Riely, Miquel Tarón, Marc Ladanyi, Belinda A. Waltman, Maureen F. Zakowski, James Chih‐Hsin Yang and William Pao and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and European Respiratory Journal.

In The Last Decade

D. M. Jackman

18 papers receiving 190 citations

Peers

Countries citing papers authored by D. M. Jackman

Since Specialization

Citations

This map shows the geographic impact of D. M. Jackman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. M. Jackman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. M. Jackman more than expected).

Fields of papers citing papers by D. M. Jackman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. M. Jackman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. M. Jackman. The network helps show where D. M. Jackman may publish in the future.

Co-authorship network of co-authors of D. M. Jackman

This figure shows the co-authorship network connecting the top 25 collaborators of D. M. Jackman. A scholar is included among the top collaborators of D. M. Jackman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. M. Jackman. D. M. Jackman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Development and Evaluation of Decision Partner: A Decision Aid for HIV Remission Clinical Trial Participation 2025 ·AIDS and Behavior ·Rebecca Moultrie, Gail E. Henderson, (unknown), (unknown), (unknown), D. M. Jackman, Stuart Rennie, Cynthia L. Gay, (unknown), (unknown), Holly L. Peay	1
2	Reactivation of Squirrel Monkey Heart Isolate (Herpesvirus saimiri strain) from Latently Infected Human Cell Cultures and Induction of Malignant Lymphoma in Marmoset Monkeys1 2015 ·Proceedings of the International Symposium on Comparative Leukemia Research ·M. D. Daniel, (unknown), D. M. Jackman, Prabhat K. Sehgal, Raymond B. Baggs, R. D. Hunt, N. W. King, L. V. Meléndez	0
3	Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy 2014 ·Clinical Radiology ·Mizuki Nishino, D. M. Jackman, Pamela J. DiPiro, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson	22
4	Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Scott Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, D. M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, Suzanne L. Topalian, F. Stephen Hodi, Mario Sznol, Christopher Harbison, Georgia Kollia, Julie R. Brahmer	15
5	Factors Associated With Survival in Patients With Oligometastatic Non-Small Cell Lung Cancer (NSCLC) 2013 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), A. Cronin, David Kozono, Geoffrey R. Oxnard, Raymond H. Mak, D. M. Jackman, Peter Lo, (unknown), Bruce E. Johnson, (unknown)	1
6	Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma 2011 ·European Respiratory Journal ·Nicolas Girard, Camelia S. Sima, D. M. Jackman, Lecia V. Sequist, (unknown), James Chih‐Hsin Yang, H Ji, Belinda A. Waltman, Rafael Rosell, Miquel Tarón, Maureen F. Zakowski, Marc Ladanyi, Greg J. Riely, William Pao	86
7	The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). 2011 ·Journal of Clinical Oncology ·Taylor M. Ortiz, Victoria A. Joshi, (unknown), Mohit Butaney, (unknown), D. M. Jackman, D J Kwiatkowski, (unknown), Pasi A. Jänne, B. E. Johnson	4
8	Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy. 2011 ·Journal of Clinical Oncology ·(unknown), B.Y. Yeap, (unknown), Michael S. Rabin, D. M. Jackman, B. E. Johnson	7
9	A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). 2011 ·Journal of Clinical Oncology ·Lecia V. Sequist, Wael A. Harb, (unknown), D. M. Jackman, Kwok‐Kin Wong, J. A. Engelman, (unknown), Matthew Onsum, (unknown)	1
10	KRAS Mutation is Associated with Decreased Overall Survival after Thoracic Radiation Therapy in Patients with Locally Advanced Non-small Cell Lung Cancer 2010 ·International Journal of Radiation OncologyBiologyPhysics ·Raymond H. Mak, (unknown), Alona Muzikansky, Joel W. Neal, Elizabeth H. Baldini, Noah C. Choi, Henning Willers, D. M. Jackman, Lecia V. Sequist	2
11	Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations. 2010 ·Journal of Clinical Oncology ·Raymond H. Mak, (unknown), Alona Muzikansky, (unknown), (unknown), Henning Willers, D. M. Jackman, Lecia V. Sequist	2
12	Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma 2009 ·Journal of Clinical Oncology ·D. M. Jackman, Leigh‐Anne Cioffredi, (unknown), (unknown), Joan Lucca, Douglas Weckstein, Mark S. Huberman, Thomas J. Lynch, Bruce E. Johnson, Pasi A. Jänne	12
13	Rates of central nervous system progression in non-small cell lung cancer patients treated with EGFR-TKI’s vs. chemotherapy 2008 ·Journal of Clinical Oncology ·Michael S. Rabin, Leigh‐Anne Cioffredi, B.Y. Yeap, (unknown), B. E. Johnson, D. M. Jackman	1
14	Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib 2008 ·Journal of Clinical Oncology ·D. M. Jackman, Lecia V. Sequist, Leigh‐Anne Cioffredi, Mariëlle Gallegos Ruiz, Pasi A. Jänne, Giuseppe Giaccone, V. A. Miller, B. E. Johnson	11
15	Phase II study of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma 2007 ·Journal of Clinical Oncology ·D. M. Jackman, Neal I. Lindeman, Joan Lucca, (unknown), Michael S. Rabin, Judith Marcoux, Mark S. Huberman, Bruce E. Johnson, Pasi A. Jänne	8
16	Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response 2006 ·Journal of Clinical Oncology ·D. M. Jackman, B.Y. Yeap, Joan Lucca, Patricia Ostler, (unknown), P. Fidias, Thomas J. Lynch, Jennifer S. Temel, Bruce E. Johnson, Pasi A. Jänne	4
17	Phase II study of the EGFR tyrosine kinase erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma 2005 ·Journal of Clinical Oncology ·D. M. Jackman, Joan Lucca, P. Fidias, Michael S. Rabin, Thomas J. Lynch, Patricia Ostler, Arthur T. Skarin, Jennifer S. Temel, Bruce E. Johnson, Pasi A. Jänne	15
18	O-188 Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma 2005 ·Lung Cancer ·D. M. Jackman, Joan Lucca, P. Fidias, Michael S. Rabin, (unknown), Patricia Ostler, AT Skarin, Jennifer S. Temel, Brent A. Johnson, Pasi A. Jänne	2
19	In vitro attenuation of herpesvirus saimiri by serial passage in dog fetal lung continuous cultures. 1975 ·PubMed ·L. V. Meléndez, D. M. Jackman, Claire Fraser, M. D. Daniel	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact